Review

The developments in paradigm of prostate cancer in recent years
  • Sertaç Yazici
  • Halil Kizilöz
  • Haluk Özen
Bull Urooncol 2014; 13: 1-7
Prognostic factors in renal cancer and prediction models
  • Ümit Gül
  • Özgür Yaycioglu
Bull Urooncol 2011; 10: 5-10
Mesane kanseri; Karsinoma In Situ (CIS)
  • Polat Türker
  • Sinan Ekici
Bull Urooncol 2011; 10: 9-12
Complications of Urinary Diversions and their Treatment
  • Eyüp Gümüs
  • Ugur Boylu
Bull Urooncol 2005; 4: 11-15
  • Hayrettin Sahin
Bull Urooncol 2011; 10: 18-20
Treatment of small renal masses: Where we are in 2011
  • Mutlu Ates
  • Mustafa Karalar
  • Engin Dogantekin
Bull Urooncol 2011; 10: 21-26
Is intravesical BCG treatment necessary and/or sufficient?
  • Sinan Ekici
  • Polat Türker
Bull Urooncol 2013; 12: 22-25
Does the Future of Prostate Cancer Treatment Lie with Apoptotic Inducers?
  • Dr. Ece Konaç
  • Dr. Sinan Sözen
Bull Urooncol 2017; 16: 22-27 DOI: 10.4274/uob.606
Benign Prostatic Hyperplasia: not recomended in diagnosis and treatment (Implented with in the historical process, but right now that is not recommended and not recommended guidelines)
  • Sakir Ongün
  • Ilhan Çelebi
Bull Urooncol 2011; 10: 23-26
Endoscopic treatment of BPH
  • Ünal Sert
  • Özcan Kiliç
Bull Urooncol 2011; 10: 30-33
Re-operation rates and possible causes related to minimally invasive and surgical treatments of Benign Prostatic Hyperplasia
  • Serdar Toksöz
  • Hakan Özkardes
Bull Urooncol 2011; 10: 34-39
Importance of mycobacteria in treatment of bladder tumor
  • Esra Büber
  • Selçuk Keskin
  • N. Leyla Açan
Bull Urooncol 2012; 11: 41-45
Active Surveillance: Treatment Modality that Expect Attention for Localized Prostate Cancer
  • Tayyar Alp Özkan1
  • Özdal Dillioglugil
Bull Urooncol 2014; 13: 41-45
Supportive treatment for patient receiving gemsitabine-cisplatine and suggestions for nursing
  • Yeter Kirdal
Bull Urooncol 2013; 12: 46-49
Is it possible to predict BCG effectivity in the treatment of superficial bladder cancer? Are there any markers?
  • Polat Türker
  • Sinan Ekici
Bull Urooncol 2012; 11: 46-51
A critical analysis of surgical curative treatments options in localised prostate cancer: open, laparoscopic, and robotassisted radical prostatectomy
  • Ender Özden
  • Yakup Bostanci
  • Yarkin Kamil Yakupoglu
Bull Urooncol 2011; 10: 47-50
The role of 5a-reductase inhibitors on prevention and hormonal treatment of prostate cancer
  • Bu¨lent Öztu¨rk
  • Tufan Çiçek
Bull Urooncol 2014; 13: 50-53
Non-Muscle Invasive Bladder Cancer: Diagnosis and Treatment of Highest-Risk Subgroup
  • Yılören Tanıdır
  • İlker Tınay
Bull Urooncol 2015; 14: 50-54 DOI: 10.4274/uob.298
Algorithmic approach to rising PSA after curative prostate cancer treatment
  • Levent Mert Günay
  • Sevket Tolga Tombul
  • Bülent Akdogan
Bull Urooncol 2011; 10: 51-55
Is TUR-B operations can be done in the office conditions by using local anesthesia
  • Tansu Degirmenci
  • Bülent Günlüsoy
Bull Urooncol 2012; 11: 52-54
Are radiological imagings useful in diagnosis, treatment and follow-up of Benign Prostatic Hyperplasia?
  • Umut Gönülalan
  • Bülent Öztürk
Bull Urooncol 2011; 10: 55-58
Outstanding variations in the treatment of prostate cancer bone metastases
  • Ibrahim Cu¨reklibatir
Bull Urooncol 2014; 13: 58-62
Role of Nanoparticles in the Treatment of Noninvasive Bladder Cancer
  • Erem Bilensoy
  • Nazlı Erdoğar
  • Aydın N. Mungan
Bull Urooncol 2015; 14: 61-66 DOI: 10.4274/uob.246
Neoadjuvant and adjuvant treatment modalities for prostate cancer
  • Erkan Erkan
  • Gökhan Toktas
Bull Urooncol 2011; 10: 63-69
The importance of cellular androgenic hormonal mechanisms in treatment and progression of prostate cancer
  • Bertrand Tombal
Bull Urooncol 2013; 12: 65-70
A New Era in Metastatic Prostate Cancer: “The Combination of Chemotherapy and Hormonal Treatment as Initial Treatment”
  • İlker Tinay
  • Levent Türkeri
Bull Urooncol 2016; 15: 65-68 DOI: 10.4274/uob.434
Targeted Therapies in Metastatic Bladder Cancer: Has It Been Approved as a Treatment Option Nowadays?
  • Nil Molinas Mandel
Bull Urooncol 2015; 14: 67-70 DOI: 10.4274/uob.2015.14.001
What is the evidence-based ideal treatment of clinical locally advanced (cT3) prostate cancer?
  • Asif Yildirim
  • Erem Kaan Basok
Bull Urooncol 2011; 10: 70-75
Hormonal treatment of metastatic prostate cancer: Today and future
  • Hasan Soydan
  • Kadir Baykal
Bull Urooncol 2011; 10: 76-81
Treatment options in low-intermediate risk prostate cancer
  • Saadettin Yilmaz Eskiçorapçi
  • Deniz Bolat
Bull Urooncol 2013; 12: 80-85
Robotic assisted laparoscopic surgery for the treatment of kidney cancer:current status in 2011
  • Cihan Toktas
  • Saadettin Eskiçorapçi
Bull Urooncol 2011; 10: 82-85
Are there any treatment option for metastatic prostate cancer refractory to docetaksel?
  • Yasar Bedük
Bull Urooncol 2011; 10: 85-89
Which Treatment Should We Prefer for High-Risk Nonmuscle Invasive Bladder Cancer? Early Cystectomy or Bladder Sparing?
  • Ali Furkan Batur
  • Sinan Sözen
Bull Urooncol 2014; 13: 93-98 DOI: 10.4274/UOB.07
Surgical treatment and/or radiotherapy in high risk prostate cancer
  • Fatih Biçaklioglu
  • Cenk Acar
  • Sinan Sözen
Bull Urooncol 2013; 12: 97-101
Is Lymphadenectomy Necessary in the Surgical Treatment of Upper Urinary Tract Urothelial Carcinoma?
  • Yakup Kordan
  • Onur Kaygisiz
Bull Urooncol 2014; 13: 99-102 DOI: 10.4274/UOB.08
The Approach to High Risk Bladder Cancers in The Absence of Bacillus Calmette Guérin: What should Be the Treatment and Follow Up?
  • Polat Tu¨rker
  • Levent Tu¨rkeri
Bull Urooncol 2014; 13: 103-108 DOI: 10.4274/UOB.09
New treatment options for the castration resistant prostate cancer targeting the androgen synthesis and androgen receptor
  • Yavuz Selim Süral
  • Çag Çal
Bull Urooncol 2013; 12: 106-110
New treatment options in castration resistant prostate cancer: enzalutamide and abiraterone acetate
  • Bülent Akdogan
Bull Urooncol 2013; 12: 111-114
Radical Prostatectomy and Lymphadenectomy in the High-Risk Prostate Cancer: Surgical Technique, Functional and Oncologic Outcomes
  • Hayrettin Şahin
  • Hasan Deliktaş
Bull Urooncol 2015; 14: 113-119 DOI: 10.4274/uob.324
New treatment options for the castration resistant prostate cancer: Cabazitaxel and Spileucel-T
  • Gürbüz Görümlü
  • Erdem Göker
Bull Urooncol 2013; 12: 115-117
New treatment options in castration resistant prostate cancer: denosumab, alpharadin
  • Hakan Gemalmaz
Bull Urooncol 2013; 12: 118-122
The Prostatic Urethral Lift Method: A New Minimally Invasive Modality as an Alternative in the Treatment of Benign Prostatic Hyperplasia
  • Alpaslan Yüksel
  • Ali Tekin
Bull Urooncol 2016; 15: 119-122 DOI: 10.4274/uob.584
Treatment Approaches for Nonmetastatic Castration-Resistant Prostate Cancer
  • Mehmet Yıldızhan
  • Hakan Gemalmaz
  • Mehmet Şirin Ertek
Bull Urooncol 2015; 14: 120-127 DOI: 10.4274/uob.328
Current Status of Laparoscopic Radical Nephroureterectomy in the Treatment Modalities for Upper Urinary Tract Tumors
  • Ahmet Gu¨deloglu
  • Cenk Yu¨cel Bilen
Bull Urooncol 2014; 13: 122-126 DOI: 10.4274/UOB.13
How shoud PSA repalse (rising PSA) be managed after radical prostatectomy? How should treatment algorithms be shaped?
  • Ilker Çelen
  • Murat Lekili
Bull Urooncol 2013; 12: 127-131
Active Surveillance in Prostate Cancer
  • Volkan İzol
  • Nebil Akdoğan
Bull Urooncol 2017; 16: 127-132 DOI: 10.4274/uob.820
Current treatment approaches in locally advanced prostate cancer: a radiation oncologist perspective
  • Ömür Karakoyun Çelik
Bull Urooncol 2012; 11: 129-133
Radical prostatectomy indications and outcomes in the high-risk localised prostate cancer
  • Hayrettin Sahin
  • Hasan Deliktas
Bull Urooncol 2013; 12: 132-136
Management of recurrences after radiation therapy used for curative intent in prostate cancer
  • Yilören Tanidir
  • Levent Türkeri
Bull Urooncol 2012; 11: 134-141
Prostate cancer in the era of robotic surgery
  • Çag Çal
Bull Urooncol 2012; 11: 150-155
‘Nanotechnology Applications’ in the Treatment of Prostate Cancer
  • Ali Furkan Batur
  • Kerem Gencer Kutman
  • Mustafa Suat Bolat
Bull Urooncol 2015; 14: 150-155 DOI: 10.4274/uob.375
Current Treatment of Testicular Sex Cord-Stromal Tumors
  • Sahin Kabay
  • Mithat Ekici
Bull Urooncol 2014; 13: 153-156 DOI: 10.4274/uob.100
Immunotherapy for the treatment of castration resistant prostate cancer: sipuleucel-T
  • Güven Aslan
Bull Urooncol 2012; 11: 156-158
Active Surveillance-Factors Affecting the Treatment Decision: 3M: “Marker”, “Mapping”, “MRI”
  • Ender Özden
  • Mehmet Necmettin Mercimek
Bull Urooncol 2015; 14: 156-160 DOI: 10.4274/uob.379
New treatment stragies in metastatic castration resistant prostate cancer: Re-Docetaxel, Abiraterone asetate, Cabazitaxel, MDV 3100
  • Sitki Ün
  • Ferruh Zorlu
Bull Urooncol 2012; 11: 159-163
Surgical Approach to the Patients with Positive Surgical Margin after Nephron Sparing Surgery
  • Bülent Günlüsoy
  • Yasin Ceylan
  • Tansu Degirmenci
Bull Urooncol 2014; 13: 165-168 DOI: 10.4274/uob.124
Current situation of the clinical stage I nonseminomatous germ cell testis tumour
  • Alim Kosar
  • Osman Ergün
Bull Urooncol 2012; 11: 181-184
Molecular Fundamentals of the Revolution in the Treatment of Renal Cell Carcinoma
  • Ece Konaç
  • Sinan Sözen
Bull Urooncol 2015; 14: 181-187 DOI: 10.4274/uob.312
Follow-up principles after curative treatment in renal cancer
  • Ercan Kazan
  • Hakan Gemalmaz
Bull Urooncol 2013; 12: 194-200
Liquid Biopsy: Circulating Tumor Cells and its Impact on Follow-up/Treatment of Prostate Cancer Patients
  • Ibrahim Kulaç
Bull Urooncol 2014; 13: 196-200 DOI: 10.4274/uob.159
The Diagnosis and Treatment of Retroperitoneal Mass
  • Ümit Gül
Bull Urooncol 2015; 14: 196-202 DOI: 10.4274/uob.419
Interventional Treatment of Benign Prostatic Hyperplasia on Elderly People: Prostatic Stent and Prostatic Arterial Embolization
  • Eray Hasirci
  • Mehmet Ilteris Tekin
Bull Urooncol 2014; 13: 210-214 DOI: 10.4274/uob.166
Active surveillence in small kidney tumors
  • Yasin Ceylan
  • Bülent Günlüsoy
Bull Urooncol 2012; 11: 212-215
Cytoreductive Nephrectomy in the Targeted Treatment Era
  • Özgür Yaycioglu
Bull Urooncol 2015; 14: 214-218 DOI: 10.4274/uob.435
Should the treatment approach be different for incidental renal tumors? Turkey databases
  • Emre Huri
Bull Urooncol 2012; 11: 216-220
Management of Upper Urinary Tract Tumors: Comparative Oncological Evaluation of Radical Nephroureterectomy and Nephron Sparing Endoscopic Treatments
  • Ali Tekin
  • Alpaslan Yüksel
Bull Urooncol 2015; 14: 223-227 DOI: 10.4274/uob.430
Open partial nephrectomy: recent situation
  • Iyimser Üre
  • Sinan Sözen
Bull Urooncol 2012; 11: 225-229
Molecular Biology in Diagnosis and Treatment of Prostate Cancer
  • Ece Konaç
  • Sinan Sözen
Bull Urooncol 2014; 13: 228-235 DOI: 10.4274/uob.194
The Treatment Modalities in Stage 1 Seminoma; Alterations in Last Five Years
  • Baris Kuzgunbay
Bull Urooncol 2015; 14: 228-231 DOI: 10.4274/uob.389
Could We Reach the Standard Treatment of Lower Urinary Tract Symptoms/Benign Prostate Hyperplasia?
  • Eray Hasirci
  • Murat Kosan
Bull Urooncol 2014; 13: 247-251 DOI: 10.4274/uob.219
Minimally invasive treatments for upper urinary tract transitional epithelial carcinoma
  • Mehmet Selçuk Keskin
Bull Urooncol 2012; 11: 252-255
Diagnostic and Prognostic Molecular Features of Urothelial Bladder Cancer and New Treatment Approaches
  • Zafer Küçükodaci
  • Kutsal Yörükoglu
Bull Urooncol 2015; 14: 258-270 DOI: 10.4274/uob.366
Surgical Treatment Options for High Risk Patients with Benign Prostatic Hyperplasia
  • Eray Hasirci
  • Ayhan Dirim
  • Hakan Özkardes
Bull Urooncol 2015; 14: 290-295 DOI: 10.4274/uob.482
The Role of Enflammation as an Etiopathogenetic Mechanism and Treatment Target in Benign Prostatic Hyperplasia
  • Ali Tekin
  • Alpaslan Yüksel
Bull Urooncol 2015; 14: 303-307 DOI: 10.4274/uob.258
The Effects of Medical Treatments Used for Benign Prostatic Hyperplasia on Ejaculation
  • Ali Kayikçi
  • Coskun Kaçagan
  • Ali Tekin
Bull Urooncol 2015; 14: 308-311 DOI: 10.4274/uob.277
Alpha Blocker Treatment and Intra-operative Floppy Iris Syndrome
  • Mehmet Emin Özyalvaçli
  • Ümit Dogan
  • Adnan Gücük
Bull Urooncol 2015; 14: 312-316 DOI: 10.4274/uob.454
Quality of Life of Patients with Advanced/Metastatic Renal Cell Carcinoma During the Treatment Period with Targeted Drugs
  • Sinharib Çitgez
Bull Urooncol 2015; 14: 321-323 DOI: 10.4274/uob.460

Radiation Oncology

Radiation therapy for bladder cancer
  • Ömür Karakoyun Çelik
  • Fatma Sert
Bull Urooncol 2012; 11: 70-73

About Journal

Forms

Useful Links

Applications